No Data
No Data
ADC Therapeutics and the Perils of Outsourced Trials: Navigating the Uncertainty of ZYNLONTA's Phase 2 Study
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
ADC Therapeutics to Present at Upcoming Investor Conferences
Little Excitement Around ADC Therapeutics SA's (NYSE:ADCT) Revenues As Shares Take 27% Pounding
Earnings Call Summary | ADC Therapeutics(ADCT.US) Q2 2024 Earnings Conference
ADC Therapeutics Second Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
No Data
No Data